21:12:39 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-26 Ordinarie utdelning 2CUREX 0.00 SEK
2023-05-25 Årsstämma 2023
2023-05-25 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2023-02-10 Extra Bolagsstämma 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-25 Ordinarie utdelning 2CUREX 0.00 SEK
2022-05-24 Kvartalsrapport 2022-Q1
2022-05-24 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-28 Ordinarie utdelning 2CUREX 0.00 SEK
2021-05-27 Kvartalsrapport 2021-Q1
2021-05-27 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-02 Extra Bolagsstämma 2020
2020-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2020-05-28 Årsstämma 2020
2020-05-28 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-22 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2019-05-28 Årsstämma 2019
2019-05-17 Kvartalsrapport 2019-Q1
2019-04-02 Extra Bolagsstämma 2019
2019-03-01 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2018-05-28 Årsstämma 2018
2018-05-18 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017


ListaFirst North Stockholm
2cureX är verksamma inom cancerbehandling. Idag tillhandahåller bolaget olika verktyg som används av läkare vid behandlingar för att mäta effekt och resistens hos cancerläkemedel på patientens egna cancerceller. Målet är att förkorta behandlingsperioden samt hitta rätt individuell behandling. Idag innehas störst verksamhet på den europeiska marknaden. Huvudkontoret ligger i Köpenhamn.
2022-01-05 09:07:00

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today that an agreement has been signed with Perlan Technologies to bring IndiTreat® tests to Polish patients and professionals.

2cureX and Perlan Technologies have signed an agreement by which Perlan Technologies becomes the distributor of IndiTreat® products in Poland. Under the terms of the collaboration, Perlan Technologies will promote IndiTreat® to Polish oncology professionals, sign supply agreements with hospitals and manage the sample logistics between the hospitals and 2cureX labs in Copenhagen.

With almost 40 million people, Poland is one of the large European markets. The country has more than 25,000 new colorectal cancer cases per year, with higher mortality rates than the European average.

Ambitious expansion strategy continues in 2022

With this agreement, 2cureX continues the ambitious expansion strategy started last year. IndiTreat® tests are currently available in 12 European countries and the company has announced plans to be in 20 countries by the end of 2022.

“This is a strong way to start the year” said Fernando Andreu, CEO of 2cureX. “Perlan Technologies has a portfolio of molecular biology products that is very complementary to IndiTreat®. It’s a great fit for us, and we are excited to welcome them to 2cureX. We are looking forward to rolling out IndiTreat® together in Poland”.

“IndiTreat® makes Perlan Technologies Oncology product offering even more complete. That we now also will be able to give patients and their doctors the drug respond information before the treatment decision is taken will for sure be of great value and appreciated” said Wojciech Duljasz, Sales Manager Diagnostics & Genomics Group of Perlan Technologies.

One of the large IVD markets in Europe

“I am glad we found the right partner to bring IndiTreat® to Poland”, said Jesper Floyd Kristiansen, VP Business Development at 2cureX. “This is a large country with an important Oncology ecosystem. There are more than 1,000 Clinical Oncologists in Poland, many of them with important positions in the international cancer scene“.

The agreement has been signed for an initial term of three years, with automatic renewal for successive terms. Other terms of the agreement have not been disclosed. Sales impact of this agreement is expected to show in 2022.